BrainStorm Receives US Patent Allowance for NurOwn Platform

- October 7th, 2019

The company received a notice of allowance for its US Patent Application called ‘Method of Qualifying Cells.’

BrainStorm Cell Therapeutics (NASDAQ:BCLI) has announced that the US Patent and Trademark Office has given a notice of allowance for its US Patent application number 15/113, 105.

As quoted in the press release:

The allowed claims cover a pharmaceutical composition for MSC-NTF cells secreting neurotrophic factors (NurOwn®) comprising a culture medium as a carrier and an isolated population of differentiated bone marrow-derived MSCs that secrete neurotrophic factors.

Patent families protecting NurOwn® have previously issued in the United States, Japan, Europe, Hong-Kong and Israel.

“This allowance further expands the patent protection of the NurOwn® Cellular Therapeutic Technology Platform and enables us to accelerate clinical development for new neurodegenerative indications,” commented BrainStorm President and CEO, Chaim Lebovits.

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

 
Read our FREE outlook report below!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *